Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Experimental Hematology
|
February 19, 2022
Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation
Enric Redondo Monte, Georg Leubolt, Roland Windisch, et al.
Hemasphere
|
March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade
Denis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Plos Genetics
|
March 19, 2016
MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO
Nicole Kohrs, Stephan Kolodziej, Olga N Kuvardina, et al.
Archives of Toxicology
|
March 29, 2018
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells
Miriam Pons, Claudia M Reichardt, Dorle Hennig, et al.
Nature Neuroscience
|
September 14, 2023
A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model
Arek Kendirli, Clara de la Rosa, Katrin F Lämmle, et al.
Biological Chemistry
|
October 30, 2021
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
Christian Kellner, Sebastian Lutz, Hans-Heinrich Oberg, et al.
Oncogene
|
March 3, 2020
ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells
Enric Redondo Monte, Anja Wilding, Georg Leubolt, et al.
Cellular and Molecular Life Sciences : CMLS
|
July 11, 2024
CD74 is a functional MIF receptor on activated CD4<sup>+</sup> T cells
Lin Zhang, Iris Woltering, Mathias Holzner, et al.
Haematologica
|
February 4, 2017
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization
Julia Schanda, Chun-Wei Lee, Katharina Wohlan, et al.
BMJ Open
|
November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Experimental Hematology
|
February 19, 2022
Specific effects of somatic GATA2 zinc finger mutations on erythroid differentiation
Enric Redondo Monte, Georg Leubolt, Roland Windisch, et al.
Hemasphere
|
March 4, 2024
Enhanced potency of immunotherapy against B-cell precursor acute lymphoblastic leukemia by combination of an Fc-engineered CD19 antibody and CD47 blockade
Denis M Schewe, Fotini Vogiatzi, Ira A Münnich, et al.
Plos Genetics
|
March 19, 2016
MiR144/451 Expression Is Repressed by RUNX1 During Megakaryopoiesis and Disturbed by RUNX1/ETO
Nicole Kohrs, Stephan Kolodziej, Olga N Kuvardina, et al.
Archives of Toxicology
|
March 29, 2018
Loss of Wilms tumor 1 protein is a marker for apoptosis in response to replicative stress in leukemic cells
Miriam Pons, Claudia M Reichardt, Dorle Hennig, et al.
Nature Neuroscience
|
September 14, 2023
A genome-wide in vivo CRISPR screen identifies essential regulators of T cell migration to the CNS in a multiple sclerosis model
Arek Kendirli, Clara de la Rosa, Katrin F Lämmle, et al.
Biological Chemistry
|
October 30, 2021
Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen
Christian Kellner, Sebastian Lutz, Hans-Heinrich Oberg, et al.
Oncogene
|
March 3, 2020
ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells
Enric Redondo Monte, Anja Wilding, Georg Leubolt, et al.
Cellular and Molecular Life Sciences : CMLS
|
July 11, 2024
CD74 is a functional MIF receptor on activated CD4<sup>+</sup> T cells
Lin Zhang, Iris Woltering, Mathias Holzner, et al.
Haematologica
|
February 4, 2017
Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization
Julia Schanda, Chun-Wei Lee, Katharina Wohlan, et al.
BMJ Open
|
November 18, 2022
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with <sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
Fiona Hegi-Johnson, Stacey E Rudd, Christian Wichmann, et al.
Page
of 6